Pathkind Labs & Roche Diagnostics partner to offer comprehensive diabetes & cardiac care

New Delhi: Pathkind Diagnostics, one of the largest pathology chains in the country is all set to transform diabetes care in India with Roche Diagnostics’ cardiac biomarker- NTProBNP that is used in the management of Type 2 Diabetes (T2DM).

NTProBNP is the gold-standard biomarker for detecting heart failure in patients and Roche Diagnostics is the only company to have received a claim extension allowing it to be used for identification of the risk of heart failure and other cardiovascular risks in people living with T2DM. With the incorporation of NTProBNP in diabetes management, Pathkind will be a leader in providing comprehensive and holistic diabetes and cardiac care.

Speaking on the occasion, Sanjeev Vashishta, MD & CEO Pathkind Labs said, “We are pleased to collaborate with Roche Diagnostics to further advance the treatment of diabetes and cardiovascular disease. Diabetes patients must receive a prompt diagnosis of heart disease in order to manage their health to the best of their ability. The co-existence of diabetes mellitus and heart failure has significant clinical and economic implications in terms of clinical visits, hospital admissions, quality of life, morbidity, and mortality. The addition of this high-sensitivity NTProBNP test will assist healthcare professionals and patients in making important medical decisions. At Pathkind, our aim is to reach out the last man even in the tier 2/3 towns with our superior quality diagnostics offering and this collaboration with Roche will strengthen our footprint in these geographies as well.”

Narendra Varde, Managing Director, Roche Diagnostics India & Neighboring Markets, said “Today, modern technology and our evolving understanding of disease have given us newer options for personalizing therapy, reducing unnecessary expenses, and protecting those in need. Incorporating NTProBNP, a simple blood test, to help detect and monitor heart failure as part of diabetes treatment and management is critical and essential. In order to lower mortality and CVD events, it is crucial to screen people with T2DM for CVD risk, therefore our partnership with Pathkind will be a turning point in diabetes management.”

In India, presently a total of 107 million adults have been diagnosed with T2DM. The prevalence of adults with pre-diabetes is much higher and is estimated to be 255 million 1. A study conducted by the Practice Innovation and Clinical Excellence (PINNACLE) India Quality Improvement Program (PIQIP) on the coexistence of T2DM and heart failure highlights that T2DM was coexistent in 23% of people with HF with reduced ejection fraction (HFrEF) 2. T2DM was a frequent comorbidity, observed in 55% of these hospitalized patients in the Trivandrum Heart-Failure Registry 2. Moreover, these studies also estimated that the annual incidence of heart failure in India is expected to increase by 18%. All the above evidence indicates that the growing burden of HF among T2DM patients requires urgent action.

According to Dr Aarti Khanna Nagpal, Pathkind Labs, “In diabetic heart failure patients, the value of NTProBNP holds a pivotal role in the evaluation of their overall status, facilitating the establishment of correct therapy management and follow-up. Evidence gathered so far highlights that NTProBNP is a direct predictor of adverse outcome and cardiovascular mortality, making this marker instrumental in the management of CVDs in T2D patients. With diabetes’ unrelenting growth, it is paramount for healthcare professionals to re-evaluate how they treat and manage a challenging patient population.”